Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lianbio ADR (NQ: LIAN )

1.670 -0.030 (-1.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31,912
Open 1.730
Bid (Size) 1.570 (4)
Ask (Size) 1.720 (20)
Prev. Close 1.700
Today's Range 1.630 - 1.730
52wk Range 1.070 - 6.240
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity... 
Via Benzinga

Performance

YTD
+6.37%
+6.37%
1 Month
-7.73%
-7.73%
3 Month
+5.70%
+5.70%
6 Month
-10.70%
-10.70%
1 Year
-40.36%
-40.36%

More News

Read More
Pfizer Opts In To LianBio Rights to Respiratory Syncytial Virus Candidate In Greater China
Via Benzinga
LianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial
Via Benzinga
LinkDoc Formally Withdraws Its U.S. IPO. Next Stop, Hong Kong?
Via Benzinga
Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore
From LianBio; Pfizer Inc.
Via Globe NewsWire
LianBio Announces President and Chief Strategy Officer Departure
From LianBio
Via Globe NewsWire
LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From LianBio
Via Globe NewsWire
LianBio to Participate in Upcoming Investor and Industry Events
From LianBio
Via Globe NewsWire
LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors
From LianBio
Via Globe NewsWire
LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
From LianBio
Via Globe NewsWire
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
From NANOBIOTIX
Via Business Wire
Week in Review: Hansoh In-licenses Endometriosis/Fibroid Therapy in $170 Million Deal
Via Talk Markets
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
4 Stocks Under $4 Insiders Are Aggressively Buying
Via Benzinga
Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company
Via Talk Markets
Mid-Afternoon Market Update: Nasdaq Down 3%; Accolade Shares Slide
Via Benzinga
70 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Mid-Day Market Update: Dow Dips 500 Points; GTY Technology Holdings Shares Jump
Via Benzinga
48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
U.S.-Bound China IPO Train Could Resume by Summer, Latest Signals Show
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.